Pharmaceutical Technology - September 2019

Pharmaceutical Technology - Regulatory Sourcebook

Issue link: https://www.e-digitaleditions.com/i/1171020

Contents of this Issue

Navigation

Page 53 of 54

54 Pharmaceutical Technology REGULATORY SOURCEBOOK SEPTEMBER 2019 P h a r mTe c h . c o m WORLDWIDE The following are some notable resources from the World Health Organization (WHO) and the International Council for Harmonization (ICH)*: WHO • WHO Resources • WHO Regulation Information • WHO Biologics Information • WHO Drug Safety ICH Resources • ICH Guidelines • ICH Reflection Papers • ICH Training ICH Guidelines • Q1A(R2) Stability Testing of New Drug Substances and Products • Validation of Analytical Procedures: Text and Methodology Q2(R1) • Impurities in New Drug Substances Q3A(R2) • Impurities in New Drug Products Q3B(R2) • Impurities: Guideline for Residual Solvents Q3C(R7) • Guideline for Elemental Impurities Q3D(R1) • Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human Or Animal Origin Q5A(R1) • Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of R-DNA Derived Protein Products Q5B • Quality of Biotechnological Products: Stability Testing of Biotechnological/ Biological Products Q5C • Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products Q5D • Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process Q5E • Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A • Specifications: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products Q6B • Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry • Pharmaceutical Development Q8(R2) • Quality Risk Management Q9 • Pharmaceutical Quality System Q10 • Q11 Development and Manufacture of Drug Substances—Questions and Answers (Chemical Entities and Biotechnological/ Biological Entities) • Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12 * Information correct as of September 16, 2019. Resources: Guidelines Contec ....................................................................................................23 Eppendorf NA ........................................................................................27 Eurofins ..................................................................................................17 PDA ...................................................................................................11, 55 Sartorius Stedim NA Inc........................................................................51 Veltek Associates ....................................................................................3 Ad Index COMPANY PAGE

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - September 2019 - Pharmaceutical Technology - Regulatory Sourcebook